How the genomic features of a patient's cancer relate to individual disease kinetics remains poorly understood. Here we used the indolent growth dynamics of chronic lymphocytic leukaemia (CLL) to analyse the growth rates and corresponding genomic patterns of leukaemia cells from 107 patients with CLL, spanning decades-long disease courses. We found that CLL commonly demonstrates not only exponential expansion but also logistic growth, which is sigmoidal and reaches a certain steady-state level. Each growth pattern was associated with marked differences in genetic composition, the pace of disease progression and the extent of clonal evolution. In a subset of patients, whose serial samples underwent next-generation sequencing, we found that dynamic changes in the disease course of CLL were shaped by the genetic events that were already present in the early slow-growing stages. Finally, by analysing the growth rates of subclones compared with their parental clones, we quantified the growth advantage conferred by putative CLL drivers in vivo.
. The two most commonly used models are exponential unbounded growth and sigmoidal growth, which stabilizes at a specific carrying capacity (for example, logistic growth). However, analyses of cancer growth patterns have so far either relied on samples with few data points per tumour or come from in vitro or mouse studies.
CLL is an informative model system for studying natural cancer growth, as it has a highly variable but often relatively indolent course, with treatment commonly withheld for months to decades until clinically necessary 11 . Temporally dense tumour measurements are feasible by serial venipuncture, which enables the analysis of growth dynamics. The availability of highly pure tumour samples has already yielded rich, unbiased genetic characterization, leading to our current detailed understanding of the genomic attributes in CLL [12] [13] [14] [15] [16] . Here, we undertake an integrative analysis of genetic data, clinical information and growth dynamics, including quantification of the effect of cancer mutations on growth rates measured in serial samples collected from 21 patients before therapy. We then corroborated the results in 86 independent patients with CLL, improving our understanding of the relationship between genotypes and phenotypes in cancer. Thus, we established a methodology and quantitative framework to model cancer growth observed directly from human patients, helping to explain the variation in the clinical behaviour of CLL.
Patterns of growth and genetic evolution in CLL
We identified 21 patients with CLL with serial samples collected between diagnosis and the start of treatment (Supplementary Table 1a ). The time to the initiation of treatment ranged from 2.1 to 15.6 years (median 5.7). The cohort was balanced for the strong prognostic marker of the mutational status of the IGH variable region (IGHV) 17 (Supplementary Methods). To assess the overall growth of the leukaemia in each patient, we evaluated 4 to 83 (median 22) pre-treatment measurements of peripheral white blood cell (WBC) counts per patient, the vast majority of which reflect CLL cells. A subset of patients exhibited bounded growth, with WBC counts plateauing over time, which suggests that the leukaemia can display logistic-like behaviour, whereas another distinct subset clearly demonstrated an exponential-like growth pattern (Fig. 1a, b, Extended Data Fig. 1b) . We therefore devised a unified Bayesian model based on a logistic pattern, as it can model both predominant growth behaviours. In this context, the posterior probabilities of the growth rate (r) and carrying capacity (K) were estimated using a Markov chain Monte Carlo (MCMC) Gibbs sampler (Supplementary Methods). The dynamics of patient WBC counts that resulted in carrying capacities confidently below 1,000 × 10 9 cells per litre were classified as exhibiting logistic (LOG) growth, whereas those confidently above 1,000 × 10 9 cells per litre were categorized as displaying exponential-like (EXP) growth. Those cases that could not be confidently attributed to either of the categories were classified as having indeterminate (IND) growth patterns.
Using this classification scheme, five patients exhibited LOG growth behaviour, with stabilization at estimated carrying capacities of 71 × 10 Table 1a) . Patients with LOG growth (4 out of 5) tended to have mutated IGHV-which is prognostically favourable-more frequently than patients with EXP growth (3 out of 10; P = 0.12; Fig. 1c ).
To examine whether genetic differences underlie the distinct patterns of growth, we performed whole-exome sequencing (WES) analysis (median coverage of 107×) on a median of 3 (range 2-6) CLL samples per patient collected before receiving therapy, spanning 0.77-10.62 (median 3.28) years between the first and last available pre-treatment time points (Supplementary Tables 1b and 2 ). Consistent with previous studies 12, 13 , we detected a median overall somatic mutation frequency of 0.79 per megabase (Mb) across patients, with frequencies of 0.19 per Mb of silent events and 0.60 per Mb for non-silent somatic single nucleotide variants (sSNVs) and 0.031 per Mb for somatic insertions and deletions (sIndels) (Supplementary Table 3 ). In addition, we identified somatic copy number alterations directly from the WES data (Supplementary Table 4) .
By comparing with previously identified putative CLL drivers 12, 13 ( Supplementary Tables 5 and 6) , we identified at least one driver in all 21 patients. We further examined whether the detected CLL drivers were clonal or subclonal by inferring their cancer cell fraction (CCF) 15 (Supplementary Methods). The total number of driver mutations was lowest in patients whose CLLs demonstrated LOG growth (median 1, range 1-4) compared with those with IND growth (median 2, range 1-2), or EXP growth (median 4, range 2-7) (P = 0.005). We identified a trend towards a higher number of clonal drivers and an increased number of subclonal drivers in samples with EXP growth compared to those with LOG or IND growth (P = 0.13 and 0.019, respectively). Finally, we saw that, even without therapy, clones with CLL drivers, occurring in samples with EXP growth, exhibited larger shifts in their clonal fractions compared with clones in samples with IND and LOG growth (P = 0.033; Extended Data Fig. 2a, b ). Most subclones with drivers present at the time of treatment were already detectable in the earliest samples.
Validation of global growth patterns
To confirm these findings, we studied an independent cohort of samples collected from 85 patients with previous characterization by WES, having at least four consecutive pre-treatment WBC measurements no more than two years apart 14, 15 (Supplementary Methods). Unlike the discovery cohort, patients in the extension cohort were not specifically selected to have undergone subsequent treatment. WES analysis was performed on samples collected at a median of 2.2 years (range 0, 18.9) after diagnosis. Of the 38 patients who subsequently underwent treatment, the median time from diagnosis to treatment was 2.6 years (range 0-18.9) (Supplementary Consistent with the results in the discovery cohort, we again found that the mutated status of IGHV was most enriched in patients with LOG growth (P = 0.002). Similarly, we found a difference in the number of total, clonal and subclonal drivers among the groups, with larger values in patients with EXP growth (P = 0.022, P = 0.011 and P = 0.017, respectively; Fig. 2b, Supplementary Table 7a, b) . Even among the 42 patients with known IGHV status in the LOG group, the 4 patients with unmutated IGHV had higher carrying capacities than the 38 patients with mutated IGHV (median of 189.2 × 10 9 versus 64.4 × 10 9 cells per litre; P = 0.017). We observed that samples with LOG growth had a higher proportion of patients that had either no known driver event or only del(13q) (51% LOG, 24% IND and 0% EXP; P = 0.001). In addition, the EXP group had a higher proportion of trisomy 12 than the IND and LOG cases (42% versus 10% and 9%, P = 0.027).
More patients with EXP and IND growth progressed to treatment than those with LOG growth (75%, 67% and 21%, P < 0.001) (Fig. 2d) . We modelled the probability of treatment using univariable exact logistic regression and stepwise multivariable logistic regression. We considered age, sex, growth pattern (EXP versus LOG, IND versus LOG), IGHV status, fluorescence in situ hybridization cytogenetics, number of drivers, and the maximum and last available WBC count before treatment as potential covariates to assess their relative contribution to clinical outcome (Supplementary Methods). In univariable analysis, growth pattern, IGHV status, del(13q), last available WBC count and the number of total and clonal drivers were significant. The final multivariable model included growth rate pattern, del(13q) and last Article reSeArcH WBC count (Extended Data Table 1 ). Growth pattern contributed significantly (EXP versus LOG: P = 0.032; IND versus LOG: P = 0.002) to a model that already included del(13q) and the last available WBC count (Fig. 2e) .
Growth patterns and evolution of relapse
Because clonal shifts were common in CLLs with more aggressive patterns of growth, we asked whether the growth pattern also affected clonal evolution after therapy. Of the 21 patients in the discovery cohort, 12 relapsed (median time from first until next treatment 1.88 years; range 0.52-5.56). Ten of these twelve patients had available post-treatment samples, which we also characterized by WES analysis.
Six of these ten patients had clear evidence of clonal evolution, characterized by a significant shift in the CCF (by 11-100%; Supplementary Methods) in at least one subclone ( Table 9 ). In the other four patients, subclones retained interclonal balance even after cytoreductive treatment (Fig. 3a, Extended Data Fig. 4b ). In two out of six evolving leukaemias, we observed evidence of convergent evolution, with several branches affecting the same pathway. In patient 5, clone 5 with the mutation encoding GNB1(I80T) disappeared, but a distinct clone with GNB1(I80N) emerged together with a mutation in CDKN2A. In patient 13, one allele of ATM was clonally mutated and the second allele had a distinct subclonal mutation of ATM. After chemotherapy, the mutated ATM subclone was replaced by an expanding clone with del(11q) that encompassed ATM and BIRC3 on one allele, and two mutations in BIRC3 on the other. The four other patients with clonal evolution after relapse also revealed emergence of clones with driver events (Extended Data Fig. 4 ). All six patients with therapy-related clonal evolution of CLL exhibited EXP growth before treatment (growth rates of 14-99% per year). By contrast, patients with preserved clonal architecture despite therapy had CLL with either LOG or IND growth (with growth rates < 31% per year) (Fig. 3a, b, Extended Data Fig. 4) . In patients from our previously reported study 15 , we found a similar association (Supplementary Methods, Supplementary four patients with data available to evaluate growth patterns (three patients included in the validation cohort of n = 85 plus one additional patient) had evolving clonal structure after relapse, and an IND or EXP growth pattern before treatment (growth rates of 32%, 64% and 138% per year), whereas the fourth patient with preserved clonal architecture despite therapy exhibited IND growth (Fig. 3, bars with  asterisks) . Overall, these results support the close association between the growth of leukaemia before treatment and clonal evolution after chemotherapy (P = 0.003).
Growth patterns of subclones
To identify whether distinct growth dynamics could be discerned among subclones underlying the overall growth patterns, we used information from macroscopic subclones (that is, having CCFs of ≥10% at one or more time points) to derive probable phylogenies for each patient (Supplementary Methods, Supplementary Table 10, Extended Data Figs. 5-7) . Using PhylogicNDT 18 , we identified subclones by n-dimensional clustering of CCFs of individual events across samples, estimated their phylogenetic relationships, and modelled the growth dynamics of each subclone (Supplementary Methods). We focused on the five patients with WES from four or more pre-treatment time points (patients 1, 4, 5, 18 and 19).
Of interest, even with overall LOG growth in the leukaemias of patients 4, 18 and 19, several subclones displayed behaviour consistent with EXP growth. Two out of four subclones (clones 1 and 3) of patient 4 had plateauing growth rates and even showed a decline in growth at the latest time point (Fig. 4a) . By contrast, the growth of clone 2 was consistent with EXP growth, providing in vivo evidence of competition among subclones within an overall picture of LOG growth of the bulk tumour. It is possible that the growth pattern of this CLL would become EXP after takeover of the cancer cell population by clone 2. In the other two patients, most clones exhibited complex dynamics that did not follow simple exponential or logistic patterns (Extended Data Fig. 6b) . Clone 3 of patient 19 exhibited mild exponential growth over time. The other clones were mostly stable with fluctuations in their abundance. Thus, for cases with overall LOG growth, we observed that complex underlying intraclonal dynamics can result in net carrying capacity.
Patients 1 and 5, who had CLL with EXP growth, also revealed diverse interclonal dynamics (Fig. 4b, Extended Data Figs. 6, 7) . Most subclones of patient 1 exhibited growth consistent with EXP patterns, with the later subclone (clone 4) probably showing faster exponential growth. In patient 5, the strongly growing subclones (clones 4 and 5) were only present in the last two time points, and thus we only tested clones 1-3 for behaviour consistent with EXP growth. Although the growth pattern of clone 1 did not fit an exponential pattern, both branches (clones 2 and 3) appeared to contribute to the overall EXP growth pattern of this case.
For added confidence and validation of the WES results, we also performed whole-genome sequencing (WGS) analysis of serial samples from a subset of cases with EXP (patients 1 and 6) and LOG (patient 4) growth patterns. The WGS results were concordant with those based on the WES data, while providing narrower credible intervals on the subclonal composition owing to an approximately 10-fold higher number of mutations per clone (Supplementary Methods, Extended Data Figs. 8, 9a-e).
Growth advantage of subclonal drivers
To quantify the growth advantage of individual subclones, we calculated the differences in growth rate (ΔGR) between child and parent clones (Supplementary Methods). We evaluated whether subclonal growth rates differed based on the presence or absence of known CLL drivers and if they had a significant selective advantage compared with the parent clone (Prob[ΔGR > 0] > 0.95, which corresponds to P < 0.05) (Supplementary Table 11 ). We focused this analysis on the 35 subclones detected in 16 patients whose leukaemias displayed overall non-logistic WBC expansion (because those with overall LOG growth lacked abundant drivers). We inferred the distribution of growth rates of individual subclones and the differences to their parents using an MCMC-based method that samples an ensemble of likely phylogenetic trees for each patient (PhylogicNDT GrowthKinetics
18
; Supplementary Methods). The model also takes into account the number of reads supporting each somatic mutation, tumour purity, absolute copy number, and the WBC measurements (Extended Data Fig. 5d) .
Indeed, 7 subclones from 6 patients (patients 1, 5, 6, 9, 13 and 14) contained a known CLL driver and their growth was significantly higher than their parent subclone (Fig. 5a, Extended Data Fig. 9f) . The strongest accelerations were associated with second hits in the tumour suppressor genes TP53 or ATM (ΔGR of 127% and 90% per year for clone 4 of patient 1 and clone 2 of patient 13, respectively). For patient 14, one subclone with several driver mutations (XPO1, del(13q) del(15q)) also expanded more rapidly than its parent (ΔGR of 57% per year). The CLL of patient 5 showed high overall growth driven by the two independent subclones containing mutations in MED12 and GNB1 (ΔGR of 41%, and 78% per year, respectively). We further saw strong growth acceleration in patient 6 (ASXL1, ΔGR of 82% per year) and in patient 9 (KRAS, ΔGR of 34% per year). These analyses provide an in vivo measurement and functional evidence of the cancer-driving capacity of these mutations. One subclone (from patient 7) had a growth rate indicative of a fitness advantage compared with its parent but without a known CLL driver (Extended Data Fig. 9g ). Its estimated ΔGR was lower than that of subclones with known drivers (ΔGR of 16% (±10% s.d.) per year). Another set of 8 subclones from 4 patients were identified to have mutations in known CLL drivers, but lacked a significant growth advantage compared with their parent subclone (for example, clone 2 in patient 3 with mutated CARD11; ΔGR 10%, P = 0.20; Extended Data Fig. 9h) In(WBC per ml) 
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and without any known CLL driver. These subclones possibly represent genetic drift 19, 20 or may have had an advantage for a short period of time (for example, clone 1 in patient 10, Fig. 5b ).
In 7 out of 16 patients, we observed more than one class of subclonal growth simultaneously (Extended Data Fig. 7) . Subclones with known CLL drivers were more likely to have accelerated growth relative to their parent (15 clones, median ΔGR of 0.23 (interquartile range (IQR) 0.02-0.71)) compared with subclones without additional known drivers (20 clones, with median ΔGR of −0.07 (IQR −0.23-0.13); P = 0.013, in a linear mixed model) (Fig. 5c) .
Finally, patients 1, 5, 6, 9 and 13 CLL had subclones with accelerated growth and branched phylogenies, providing opportunities to examine the relative fitness advantage that is conferred by drivers to the subclone within specific genetic contexts. For example, the acquisition of amp(5q34) and del(17p) in clone 4 (patient 1) seems to confer faster growth than clones with the TP53 mutation alone (clone 2), del(11q) and amp(8q) (clone 1) or with the FAM50A mutation (clone 3) in the context of clonal SF3B1 mutation. Similarly, in patient 6, clone 3 had a mutation in ASXL1 in the context of clonal del(13q) and del(11p) and expanded faster than a sibling clone having amp(2p) and del(6q) mutations. With sufficiently large multi-time point sequencing datasets and overall tumour burden information (that is, WBC counts), comparing the growth of sibling clones will enable the construction of a map of the fitness of driver events in specific genetic contexts.
Discussion
Many mathematical models have been proposed to describe cancer growth in patients, but with no consensus [7] [8] [9] . Previous works reported exponential growth in leukaemia, lung, liver and breast cancer 7, 8 , and sigmoidal growth (such as logistic or Gompertz) in earlier studies of breast cancer 4, 5 and in xenografts derived from human colorectal cancer 6 . Our study shows that individual cancers of the same type can exhibit diverse growth patterns: whereas many patients with CLL exhibited exponential-like growth with high or unbounded carrying capacity, in others, the disease achieved a-potentially temporary-stable state, and exhibited a logistic-like pattern with finite carrying capacity. For these distinct growth classes, we further identified clear differences in genetic attributes and clinical outcomes: exponential growth was associated with a larger number of CLL drivers, greater subclonal dynamics and an earlier need for treatment. Conversely, logistic growth was associated with a narrower spectrum of genetic alterations, fewer subclonal drivers, and interclonal stability even in relapse after treatment. We and others previously noted that del(13q) and trisomy 12 are probable early events in CLL phylogeny 13, 21 , and we found that the presence of del(13q) is associated with logistic growth, whereas trisomy 12 was associated with exponential growth. Our multivariable analysis demonstrated that the incorporation of growth pattern behaviour provides additional explanatory power above that provided by the presence of the strong prognostic cytogenetic marker of del(13q) 22 , and was stronger than the mutational status of IGHV 17 . Furthermore, the genetic diversity of CLL seems to be established early in the disease, consistent with previously reported smaller series [23] [24] [25] . In the absence of therapeutic perturbations, the observed rate and pattern of outgrowth of CLL over time thus seems to 'play out' the pre-determined genetic and clonal composition. Of note, the growth rates of these clones from untreated patients are several-fold lower than that of relapse clones we previously reported in patients receiving ibrutinib 2 . Recent studies to characterize genetically the premalignant states of solid tumours 26 , and of monoclonal B cell lymphocytosis 27, 28 (considered a precursor condition of CLL), have further supported the idea that the extent of genetic diversity of malignancies such as CLL long predates its fullblown clinical picture.
Our approach of integrating patient tumour burden measurements and sequencing data from several disease time points provides a conceptual framework for understanding the growth trajectories of individual populations of CLL cells. We detected evidence of in vivo competition among subclones in early CLL and more atypical behaviours that could not be categorized using simple models, extending previously reported insights on CLL evolution during later periods of the disease course [29] [30] [31] . For example, in a subset of patients, we observed a shift from overall logistic growth, with many years spent at carrying capacity, to exponential growth.
Finally, our computational framework enabled us to quantify the degree of growth acceleration and fitness of genetically defined subclones over their parental clones. Accelerated growth was strongly enriched in subclones with well-established CLL drivers. Thus, we provide evidence of ongoing evolution in vivo, with clear growthaccelerating roles and potential synergies of driver mutations. We also find frequent existence of growth-neutral subclones without drivers, probably representing genetic drift 19, 20 . These fundamental findings are especially relevant to the ongoing efforts of precision oncology, in which the estimation of clonal growth dynamics in individual patients may inform therapy and predict the course of their disease.
Reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
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